Evidence map›Paper›PMID 29515623›Full record

ArticleFrontiers in genetics2018

Growth of Malignant Non-CNS Tumors Alters Brain Metabolome.

Anna Kovalchuk, Lilit Nersisyan, Rupasri Mandal, David Wishart, Maria Mancini, David Sidransky, Bryan Kolb, Olga Kovalchuk

Open access · goldAbstract read
In one paragraph

Article in Frontiers in genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Anna KovalchukDepartment of Neuroscience, University of Lethbridge, Lethbridge, AB, Canada.
Lilit NersisyanGroup of Bioinformatics, Institute of Molecular Biology, National Academy of Sciences, Yerevan, Armenia.
Rupasri MandalThe Metabolomics Innovation Center, Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
David WishartThe Metabolomics Innovation Center, Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Maria ManciniDepartment of Oncology, Champions Oncology, Baltimore, MD, United States.
David SidranskyDepartment of Oncology, Champions Oncology, Baltimore, MD, United States.
Bryan KolbDepartment of Neuroscience, University of Lethbridge, Lethbridge, AB, Canada.
Olga KovalchukDepartment of Biological Sciences, University of Lethbridge, Lethbridge, AB, Canada.
University of Lethbridge · CAChampions Oncology (United States) · USNational Academy of Sciences of Armenia · AMThe Metabolomics Innovation Centre · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer survivors experience numerous treatment side effects that negatively affect their quality of life. Cognitive side effects are especially insidious, as they affect memory, cognition, and learning. Neurocognitive deficits occur prior to cancer treatment, arising even before cancer diagnosis, and we refer to them as "tumor brain." Metabolomics is a new area of research that focuses on metabolome profiles and provides important mechanistic insights into various human diseases, including cancer, neurodegenerative diseases, and aging. Many neurological diseases and conditions affect metabolic processes in the brain. However, the tumor brain metabolome has never been analyzed. In our study we used direct flow injection/mass spectrometry (DI-MS) analysis to establish the effects of the growth of lung cancer, pancreatic cancer, and sarcoma on the brain metabolome of TumorGraft™ mice. We found that the growth of malignant non-CNS tumors impacted metabolic processes in the brain, affecting protein biosynthesis, and amino acid and sphingolipid metabolism. The observed metabolic changes were similar to those reported for neurodegenerative diseases and brain aging, and may have potential mechanistic value for future analysis of the tumor brain phenomenon.

Indexed as

animal modelsbrain agingmetabolomics/metabolite profilingnon-CNS tumorstumor brain

Identifiers

PMID29515623
PMCPMC5826252
OpenAlexW2792094619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.